# A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations

> **NCT01287754** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 24 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** erlotinib [Tarceva]

## Key facts

- **NCT ID:** NCT01287754
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2015-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01287754

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01287754, "A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01287754. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*